Efficacy News and Research

RSS

Investigational drug shows promise in ovarian cancer

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

Inovio Biomedical achieves 75% complete response rate in preclinical testing of DNA-based cancer vaccine using its electroporation DNA delivery system

Inovio Biomedical Corporation announced today that it achieved positive results from its proprietary research and development program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology.

15 Sep 2008

Keppra XR approved in the U.S. for partial onset seizures

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra XR (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial onset seizures who are 16 years of age and older. Keppra XR is expected to be available in U.S. pharmacies at the end of September 2008.

15 Sep 2008

Phase I trial for new tuberculosis vaccine

This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.

11 Sep 2008

New drug promises once-a-day treatment for asthma and hay fever

The drug RPL554 apparently has the potential to effectively treat the respiratory diseases but without many of the side-effects most currently available drugs produce.

10 Sep 2008

60% of women use herbal products during pregnancy

Almost 60% of women use at least one herbal product during pregnancy, research launched at the British Pharmaceutical Conference (BPC) in Manchester has revealed.

7 Sep 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Nanotherapeutics files INDA for NanoDOX hydrogel to treat type of diabetic ulcers

Nanotherapeutics announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Sep 2008

Unsuccessful drug against anxiety opens a novel gateway for the treatment of cancer

According a new study, unsatisfying drug for anxiety reveals scientists a promising novel anti-cancer drug target.

4 Sep 2008

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

4 Sep 2008

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Cancer drug developer Antisoma plc today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Diffusion Pharmaceuticals initiates phase I/II clinical trial in patients with peripheral arterial disease

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).

3 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

Alte Biosciences files patent for novel inflammatory bowel disease drugs

Alte Bioscience, Inc., a development stage pharmaceutical company, is pleased to announce the filing of a provisional patent for a new class of drugs that may benefit patients with inflammatory bowel disease.

3 Sep 2008

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

Biotech company Pharming Group NV has announced that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

3 Sep 2008